KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy | Zendy

Chiara Ambrogio | Zendy; Ernest Nadal | Zendy; Alberto Villanueva | Zendy; Gonzalo GómezLópez | Zendy; Timothy P. Cash | Zendy; Mariano Barbacid | Zendy; David Santamarı́a | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy

Author(s) -

Chiara Ambrogio,

Ernest Nadal,

Alberto Villanueva,

Gonzalo GómezLópez,

Timothy P. Cash,

Mariano Barbacid,

David Santamarı́a

Publication year - 2016

Publication title -

esmo open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.409

H-Index - 31

ISSN - 2059-7029

DOI - 10.1136/esmoopen-2016-000076

Subject(s) - kras , adenocarcinoma , cancer research , carcinogenesis , oncogene , lung cancer , viral oncogene , biology , targeted therapy , notch signaling pathway , cancer , computational biology , gene , pathology , medicine , mutation , genetics , cell cycle

Understanding the early evolution of cancer heterogeneity during the initial steps of tumorigenesis can uncover vulnerabilities of cancer cells that may be masked at later stages. We describe a comprehensive approach employing gene expression analysis in early lesions to identify novel therapeutic targets and the use of mouse models to test synthetic lethal drug combinations to treat human Kirsten rat sarcoma viral oncogene homologue (KRAS)-driven lung adenocarcinoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research